- Home
- / Atara Biotherapeutics
Atara BiotherapeuticsAtara Biotherapeutics
Phase III Trials Products
1
FY, 2016
Market Capitalization
$371.4 M
2022-11-21
Atara Biotherapeutics Summary
Company summary
- Overview
- Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara operates through the business of developing and commercializing therapeutics segment.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- South San Francisco, CA, US | view all locations
- Website
- http://atarabio.com/
- Cybersecurity rating
- ESG rating
Key people
Eric Dobmeier, Director
Roy D Baynes, Director
Ron Renaud, Chairman of the Board
Operating MetricsView all
Phase III Trials Products
1
FY, 2016
Phase II Trials Products
3
FY, 2016
Phase I Trials Products
3
FY, 2016
LocationsView all
7 locations detected
South San Francisco, CA HQ
United States
Building 83, 611 Gateway Blvd #900
Aurora, CO
United States
12635 E Montview Blvd #280
New York, NY
United States
135 E 57th St 14th Floor
Thousand Oaks, CA
United States
2380 Conejo Spectrum St #200
Reykjavík
Iceland
Kalkofnsvegur 2
Mocejón, CM
Spain
Atara Biotherapeutics Financials
Summary financials
- Net income (Q3, 2022)
- ($84.1M)
- EBIT (Q3, 2022)
- ($84.6M)
